Standout Papers

Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Reti... 2019 2026 2021 2023 268
  1. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy (2019)
    Albert M. Maguire, Stephen R. Russell et al. Ophthalmology

Immediate Impact

9 by Nobel laureates 35 from Science/Nature 76 standout
Sub-graph 1 of 20

Citing Papers

Gene Editing for CEP290 -Associated Retinal Degeneration
2024 Standout
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
21 intermediate papers

Works of Daniel C. Chung being referenced

How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease
2019
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
2012
and 10 more

Author Peers

Author Last Decade Papers Cites
Daniel C. Chung 2494 865 791 70 3.3k
Michael L. Robinson 3823 537 884 104 5.4k
Douglas B. Gould 1908 871 789 69 3.8k
Amir Rattner 4048 644 636 62 5.3k
M. Sarfarazi 1697 410 806 65 2.9k
John R.W. Yates 2193 1213 1418 80 5.3k
Jochen Graw 3931 1017 1327 158 5.6k
Lihua Y. Marmorstein 2319 1057 925 47 3.4k
Alfons Meindl 3400 402 2006 76 5.6k
Hélène Dollfus 4736 1218 2890 175 6.6k
Lies H. Hoefsloot 3558 534 1663 135 6.4k

All Works

Loading papers...

Rankless by CCL
2026